Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu klinické zkoušky, klinické zkoušky, fáze IV, časopisecké články, multicentrická studie
PubMed
32060515
PubMed Central
PMC7476636
DOI
10.1093/ecco-jcc/jjaa027
PII: 5736390
Knihovny.cz E-zdroje
- Klíčová slova
- Clinical trials, Crohn’s disease, Vedolizumab, ulcerative colitis,
- MeSH
- Crohnova nemoc * diagnóza farmakoterapie imunologie MeSH
- dospělí MeSH
- gastrointestinální látky aplikace a dávkování škodlivé účinky farmakokinetika MeSH
- humanizované monoklonální protilátky * aplikace a dávkování škodlivé účinky farmakokinetika MeSH
- imunologická odpověď na dávku MeSH
- integriny antagonisté a inhibitory MeSH
- intravenózní infuze MeSH
- lidé MeSH
- monitorování léčiv metody MeSH
- ulcerózní kolitida * diagnóza farmakoterapie imunologie MeSH
- vysazování léků metody MeSH
- výsledky a postupy - zhodnocení (zdravotní péče) MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze IV MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- Názvy látek
- gastrointestinální látky MeSH
- humanizované monoklonální protilátky * MeSH
- integriny MeSH
- vedolizumab MeSH Prohlížeč
BACKGROUND AND AIMS: Vedolizumab was shown to be safe and effective for the treatment of Crohn's disease [CD] and ulcerative colitis [UC] in the GEMINI Long-Term Safety [LTS] study. The vedolizumab Extended Access Program [XAP] provides patients with continued treatment. This XAP pharmacokinetics [PK] sub-study investigated vedolizumab efficacy, safety, and PK. METHODS: Vedolizumab dosing frequency was reduced from every 4 weeks [Q4W] to every 8 weeks [Q8W] at XAP enrolment, and patients were followed for 56 weeks. Outcomes included: efficacy, loss of clinical benefit, and re-escalation to Q4W dosing; and vedolizumab PK, immunogenicity, and adverse events. RESULTS: Among 167 enrolled patients [CD = 88, UC = 79], 80 [91%] with CD and 73 [92%] with UC completed 56 weeks; 76 [86%] and 71 [90%] with CD and UC, respectively, remained on Q8W dosing for 56 weeks. Clinical remission, corticosteroid-free clinical remission, and C-reactive protein levels were stable among patients remaining on Q8W through Week 56. Four patients with CD and two with UC resumed Q4W dosing [three with CD regained clinical response]. Patients with CD who completed Week 56 on Q8W dosing had median trough vedolizumab concentrations of 43.6 µg/mL at enrolment and 10.4 µg/mL at Week 56; concentrations were 42.4 µg/mL and 13.3 µg/mL, respectively, in patients with UC. Treatment-related adverse events were infrequent; no new or serious adverse events related to vedolizumab were reported. CONCLUSIONS: In the XAP-PK sub-study, adherence to Q8W dosing was high, with no loss of efficacy; very few patients required re-escalation to Q4W. There were no new safety signals.
Department of Gastroenterology and Hepatology University Hospitals Leuven Leuven Belgium
Department of Gastroenterology Centro Hospitalar São João Porto Portugal
Department of Gastroenterology IBD Center Humanitas Research Hospital Rozzano Italy
IBD Clinical and Research Centre ISCARE Clinical Centre Prague Czech Republic
Zobrazit více v PubMed
Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012;380:1590–605. PubMed
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606–19. PubMed
Briskin M, Winsor-Hines D, Shyjan A, et al. . Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97–110. PubMed PMC
Erle DJ, Briskin MJ, Butcher EC, Garcia-Pardo A, Lazarovits AI, Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol 1994;153:517–28. PubMed
Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864–75. PubMed
Feagan BG, Rutgeerts P, Sands BE, et al. ; GEMINI 1 Study Group . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710. PubMed
Sandborn WJ, Feagan BG, Rutgeerts P, et al. ; GEMINI 2 Study Group . Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369:711–21. PubMed
Danese S, Sandborn WJ, Colombel JF, et al. . Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. Gastroenterology 2019;157:1007–18.e7. PubMed
Entyvio [Vedolizumab] [Package Insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2018.
Vedolizumab [Summary of Product Characteristics]. Taastrup, Denmark: Takeda Pharma A/S; 2019.
Loftus EV Jr, Colombel JF, Feagan BG, et al. . Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis 2017;11:400–11. PubMed
Vermeire S, Loftus EV Jr, Colombel JF, et al. . Long-term efficacy of vedolizumab for Crohn’s disease. J Crohns Colitis 2017;11:412–24. PubMed
Rosario M, Dirks NL, Gastonguay MR, et al. . Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther 2015;42:188–202. PubMed PMC
Al-Bawardy B, Ramos GP, Willrich MAV, et al. . Vedolizumab drug level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease. Inflamm Bowel Dis 2019;25:580–6. PubMed
Schulze H, Esters P, Hartmann F, et al. . A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. Scand J Gastroenterol 2018;53:670–6. PubMed
Ungaro RC, Yarur A, Jossen J, et al. . Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease. J Crohns Colitis 2019;13:963–9. PubMed PMC
